BioSpace News Archive

Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, reported financial results for the second quarter ended June 30, 2019 and provided an update on corporate progress.

Another successful outcome from a Versant-created company in a breakthrough field

DW Healthcare Partners (“DWHP”), a healthcare-focused private equity firm, announced today a majority investment in CEFALY Technology SPRL (“CEFALY”), a leading global manufacturer and marketer of neuro-modulating medical devices for the prevention and treatment of migraines.

89Bio Ltd. (89bio), a clinical-stage biopharmaceutical company, today announced that the first patients have been screened in its proof of concept Phase 1b/2a clinical trial evaluating its investigational product candidate, BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), in patients with nonalcoholic steatohepatitis (NASH) or patients with nonalcoholic fatty liver disease (NAFLD) and high risk of NASH.

Prometic Life Sciences Inc., wishes to correct an error in its press release entitled “Prometic to report its second quarter financial results and hold a conference call” issued on August 7th, 2019.

PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, reported financial results for the second calendar quarter of 2019.

Bayer AG and BlueRock Therapeutics announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell platform.

Sierra Oncology, Inc. reported its financial and operational results for the second quarter ended June 30, 2019.

AVEO Oncology reported financial results for the second quarter ended June 30, 2019 and provided a business update.

Bicycle Therapeutics plc reported financial results for the second quarter ended June 30, 2019 and provided a clinical update.